Vivek Podder, MBBS

For breast cancer, metastatic progression occurred in 10.2% using GLP-1 versus 20.1% who did not! That is a larger risk reduction than most novel therapeutics. While retrospective data, this is truly compelling enough the study prospectively and understand mechanism! Now who will do it?? @novonordisk @LillyMedical @Neil_Iyengar GLP-1 RA Exposure After Diagnosis Could Lead to Reduced Progression, Improved Survival in Multiple Malignancies dailynews.ascopubs.org/do/glp-1-recep…

Don’t miss the new #IJGCconversations episode with Dr. Robert Coleman @rcoledude 🎙️✨ Vaccine Therapy in Ovarian Cancer: Role of Gemogenovatucel-T 💉🧬 Tune in and explore the future of immunotherapy in #ovariancancer! 🎧 bit.ly/42LCWuH @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @ElePanizzolo @esragbilir @ChiaraAinio @alicezampolini @Chiara_4997 @Lawalqdus @kamillaldavid @Dra_AnaConde

🚨 New #IJGCconversations episode! Ribociclib ➕ Letrozole in Recurrent Low-Grade Serous Carcinoma of the Ovary: #GOG3026 with Brian Slomovitz @gyncancerMD and David Gershenson @RareOvarCancers 🎧 Tune in now: bit.ly/4uIhxyx @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @ElePanizzolo @esragbilir @ChiaraAinio @alicezampolini @Chiara_4997 @Lawalqdus @kamillaldavid @Dra_AnaConde

🎙️ New #IJGCconversations @pedroramirezMD speaks with Dr Vivek Podder 🇺🇸 & Dr Brian M. Slomovitz @GynCancerMD on the evolving role of #GLP-1 receptor agonists in #endometrial cancer—#metabolism, #obesity & oncologic outcomes 🎧 Listen now: bit.ly/4cyNl2E 🌍 @MountSinaiMiami @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @RParejaGineOnco @lchiv4 @annafagottimd @HousseinELHAJJ3 @AinhoaMada @luribero26 @beatesarta @AlwynDO @PeppeParisi_ @ilkerselcukmd @VinTarantino @NSeminario27498 @dranushak88 @richaga32907418 #WeeklyPodcast #IJGConline #Research #Prevention #Treatment #Diagnostic #GynCancer #GynOnc #WomenHealth #SoMe #SoMe4GynOnc

💡 JAMA Insights: Numeric risk comparisons anchored in patient context may improve shared decision-making and help patients interpret clinical choices. ja.ma/4sXLpFP

A MUST-READ! This is probably one of my most important papers where I try to teach how to fish rather than offer fish. How I Read a Clinical Trial Report? BG’s primer for Busy Clinicians. Thank you @JCOOP_ASCO @EthicsdoctorP for the kind invitation. I hope the readers will find this useful. ascopubs.org/doi/10.1200/OP…

When God has a plan… From selling bhatura chole at Vivek Public School in 1989, to opening Lawrence Garden Banquet from the back of my house in Amritsar in 1990. In 1991, I chose culinary arts— a decision that embarrassed almost everyone except my grandmother. There were years of humiliation I rarely speak about. Moments that nearly broke me. In 2000, when my banquet was torn down, I almost gave up. Instead, I moved to the United States and started over. Cleaning homes. Selling food on the streets of TriBeCa. Sleeping at Grand Central. Experiencing homelessness at NYC Rescue. Sleepless nights. Being called “Curry Boy” on the 7 train. And still, I kept going. From there… 8 Michelin stars. Then losing myself again. Then starting over—one last time as a promise to my sister—with Bungalow. And now… TIME100 Most Influential People in the World 2026. I’m still trying to process it. The journey continues.

The @NCCN has updated its 2026 Clinical Practice Guidelines in oncology for breast cancer screening and diagnosis to include Clairity Breast, an AI-based risk assessment tool that analyzes mammograms and assesses patients’ future risk for breast cancer development #bcsm #oncology Read more: onclive.com/view/clairity-…

For more information on these Posters being presented at SGO 2026, click link in bio or go to ow.ly/qmf250YGI2R. #GOGF #GOGP #clinicaltrials #gynecologiconcology

South Asian adults in the US develop cardiovascular disease risk factors earlier than other groups, according to new research from the MASALA cohort study. Here’s what that means for prevention. ja.ma/4t8wSIt

Going to be a great sgo. Congrats @PamSolimanMD program director (my co-fellow) and @karenluMD, SGO President (one of my mentors and my fellowship research boss) for organizing a great meeting. It’s going to be fun and educational!!

In a randomized controlled study of 1,298 participants, performance of humans when assisted by an #LLM was inferior to the LLM alone when assessing 10 medical scenarios. nature.com/articles/s4159…

⭐️Wow 👉🏼published in @Nature 👉🏼“Thymic health and immunotherapy outcomes in patients with cancer.” ⭐️Across melanoma, breast, & renal cancers, the signal is clear: thymic health is a pan‑cancer, #tumoragnostic determinant of immunotherapy efficacy. ⭐️I think there are huge implications for patient stratification, treatment timing, & immune‑rejuvenating strategies in #PrecisionMedicine here @OncoAlert nature.com/articles/s4158…

#Obesity is associated with higher risk for 12 #cancer types and accounts for approximately 10% of annual new cancer cases in the US. 📄 This Review summarizes the primary biological pathways connecting obesity and cancer development. ja.ma/3OPhtgT

@amazon One of the worst customer service experiences I have encountered. Multiple cancellations, account flags, repeated refund promises not honored, and inconsistent interactions from associates. Far from the customer-centric positioning. @ajassy @AmitAgarwal @JeffBezos

Now online: Repositioning GLP-1 Receptor Agonists in Endometrial Cancer: Molecular Rationale, Preclinical Insights, and Translational Opportunities doi.org/10.1158/1078-0…

Editorial: Comparative efficacy between 400-mg and 600-mg ribociclib doses in hormone receptor–positive breast cancer is clinically minimal, but differences in toxicity are significant. ja.ma/4ih8jV1

Join us for November Journal Club!  Wednesday, November 19th, 2025 11:00-11:45 CST (18:00-18:45 CET). November Lead Article for Discussion: Checkpoint inhibitor rechallenge in advanced endometrial cancer: revisiting the immune landscape beyond first-line therapy igcs.org/ijgc-journal-c…

✨ Don’t miss our next #IJGCclub! 🗓️ Nov 19 | 11:00 CDT (18:00 CEST) 📖 Checkpoint inhibitor rechallenge in advanced endometrial cancer with Brian M. Slomovitz, MD @GynCancerMD and Vivek Podder @VPodder (@SinaiHealth) 🔗 Don’t miss this engaging discussion: bit.ly/4jfSMEP @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @IJGCfellows @OncoAlert @GynMe4 @RParejaGineOnco @lchiv4 @annafagottimd @HousseinELHAJJ3 @AinhoaMada @MathildeDel2 @DrPervan @T_Meschini @moe_byrneMD @MatteoLoverro @CSabiniMD @ZaniruRaul #IJGConline #Research #Prevention #Treatment #Diagnostic #GynCancer #GynOnc #WomenHealth #SoMe #SoMe4GynOnc